Novavax Q1 revenue $667M, net income $519M; raises FY guidance to $975M-$1.025B

NOVAVAX INC

2025-Q1 EPS reported $2.93 revenue$666,655,000

Total revenue $667M vs $94M YoY; net income $519M vs net loss $148M.
Raises full-year adjusted total revenue framework to $975M-$1,025M (from $300-$350M).
FDA BLA review on track; approval triggers $175M milestone from Sanofi; MAs to Sanofi by Q4 2025.
Strengthened Takeda partnership: $20M upfront, annual milestones plus royalties on Japan sales.
SHIELD-Utah: Nuvaxovid recipients had ~39% fewer reactogenicity symptoms vs mRNA vaccine.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.